Lupin has gained by 1% at Rs 445 after it announced on Friday afternoon that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received tentative approval for its Duloxetine Hydrochloride Delayed-release (HCl DR) Capsules 20 mg, 30 mg and 60 mg from the United States Food and Drugs Administration for the company’s Abbreviated New Drug Application (ANDA) to market a generic version of Eli Lily & Company’s Cymbalta® Delayed-release Capsules.
Lupin’s Duloxetine HCl DR Capsules are the AB-rated generic equivalent of Eli Lily’s Cymbalta® Delayed-release Capsules 20 mg, 30 mg and 60 mg strengths. Duloxetine HCl DR Capsules is indicated for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy, management of fibromyalgia (FM) and management of chronic musculoskeletal pain.
In the intraday deal, the stock opened at Rs 443 and made a high of Rs 447.35. Around 181 shares were traded in BSE so far.
